Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23.

¹ Rheumatology Department, Azienda USL Toscana Centro, Hospital of Prato, Piazza Ospedale 1. Electronic address: fbrzcantini@gmail.com.
² Rheumatology Department, Azienda USL Toscana Centro, Hospital of Prato, Piazza Ospedale 1.
³ Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: daniela.matarrese@uslcentro.toscana.it.
⁴ National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Via Portuense, 292, Rome 00149, Italy. Electronic address: emanuele.nicastri@inmi.it.
⁵ AOS Antonio e Biagio e C. Arrigo, Rheumatology Unit - Alessandria, Italy. Electronic address: pstobbione@ospedale.al.it.
⁶ National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Via Portuense, 292, Rome 00149, Italy; Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Via Portuense 292, 00149 Rome, Italy. Electronic address: delia.goletti@inmi.it.

Abstract

Image, graphical abstract